Time-points
tobacco addiction, obstructive symptoms
DISEASE, RECURRENCE, COMPLICATIONS, STENOSES
Screening and Inclusion: Eligibly criteria will be assessed, and the number and extent of the stenoses together with the patient’s CD clinical status will be evaluated. In addition, the patients’ demographic data will be collected and quality of life pre-treatment assessed. Patients will be randomly assigned to a treatment group.Treatment procedure: Relevant procedure-related information will be gathered, such as duration of procedure, materials, number and type of personnel involved, pharmacological treatment, and technical success. Pharmacological treatment, complications, and incidents will also be noted.Follow-up: After treatment procedure, patients will be assessed in a face-to-face visit, or with a telephone call, on days 7 and 30, and every month until reaching 1-year follow-up. A record will be kept of the therapeutic requirements, complications, and/or incidents, as well as an assessment of active smoking status. In cases of tobacco addiction, an active policy aimed at elimination will be implemented.A follow-up telephone call on the seventh day post-procedure and subsequently each month will be made to record AEs and the presence of obstructive symptoms. Face-to-face visits will be scheduled during the first and sixth months, and at the end of the follow-up (1 year). In addition to AEs and obstructive symptoms, a clinical assessment of disease activity (CDAI and inflammatory markers in blood) will be carried out. Moreover, an assessment of quality of life will be done at the sixth month and at the end of follow-up. Endoscopy will be performed 6 months after procedure to assess the occurrence of recurrence and escalation of treatment if necessary (in the case of surgical treatment: Rutgeerts index i2b-i4).End of study: After completing 1-year follow-up or in case of discontinuation in the study, the following data will be compiled: reason for the end of follow-up, treatments performed, duration of follow-up, and treatment’s clinical success.